This free survey is powered by QUESTIONPRO.COM
  1. Surveys
  2. 2012
  3. October
  4. P
  5. Post-meeting survey.v01
0%
Exit Survey »
 
 
The objective of this survey is to assess the progress made in achieving the major goals of the Global Pipeline Summit 2012. The survey is designed to capture attendee feedback on specific events and sessions, as well as general input on the Summit.

Your responses are critical to evaluate the conference, and your experiences will inform future Summit planning. Thank you in advance for your participation.
 
 
 
In your role, what is your area of geographic coverage? (Please select one)
 
Global
 
International HQ
 
Area – CEE/NWA
 
Area – AAAME
 
Area – WE&C
 
Area – LA
 
Area – Japan
 
Area – U.S.
 
Affiliate (Please specify)
 
 
 
 
Which of the following best describes your functional area? (Please select one)
 
Market Access / Pricing
 
Government Affairs
 
HEOR
 
Commercial
 
Clinical Development
 
Medical Affairs
 
Regulatory
 
Manufacturing
 
Other (Please specify)
 
 
 
 
Which of the following therapeutic areas do you cover? (Please select all that apply)
 
Immunology
 
Pain
 
Renal
 
Oncology
 
Virology
 
Neuroscience
 
Women’s Health
 
Other (Please specify)
 

 
 
 
Which Plenary session(s) did you attend? (Please select all that apply)
 
Opening Plenary
 
Presentation by Rick Gonzalez
 
Closing Plenary
 
I did not attend any Plenary session

 
 
Consider your experience at the Opening Plenary (Wednesday). Please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
The session met my expectations and was an effective way to begin the summit
I learned something new and/or important during this session
The presenters were engaging and motivating
The length was appropriate
The format was appropriate
 
 
Consider your experience at the presentation by Rick Gonzalez (Thursday). Please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly agree 2 3 4 = Neutral 5 6 7 = Strongly agree
It was valuable and important to see the leader of AbbVie at this event
This session helped put the pipeline in the larger context of the company’s future
The timing of this session within the overall schedule of events was effective
The presentation met my expectations
 
 
Consider your experience at the Closing Plenary (Friday). Please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly agree 2 3 4 = Neutral 5 6 7 = Strongly agree
The session met my expectations and was an effective way to end the summit
The session presented an appropriate forum to answer my questions
The presenters were engaging and motivating
The length was appropriate
The format was appropriate
I left the summit with a clear view of the next steps
 
 
 
What was the best part of the plenary sessions? Why?
   
 
 
 
What aspect of the plenary sessions would you like to see improved? What suggestions do you have for improvements?
   
 
 
 
Which Key Compound Breakout sessions did you attend? (Please select all that apply)
 
HCV
 
ABT-719
 
Daclizumab
 
ImmunOP
 
I did not attend any Key Compound Breakout Sessions

 
 
For the HCV Key Compound Breakout, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
For the ABT-719 Key Compound Breakout, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
For the Daclizumab Key Compound Breakout, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
For the ImmunOP Key Compound Breakout, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
 
Please provide additional feedback on any aspect of the Key Compound Breakouts, and list any suggestions you have for improvements.
   
 
 
 
Which Expert Session did you attend? (Please select all that apply)
 
Immunology
 
ABT-126
 
Oncology
 
Elagolix
 
Humira (Hidradenitis Suppurativa)
 
Humira (Uveitis)
 
I did not attend an Expert Session

 
 
For the Immunology Expert Session, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
For the ABT-126 Expert Session, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
For the Oncology Expert Session, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
For the Elagolix Expert Session, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
For the Humira (Hidradenitis Suppurativa) Expert Session, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
For the Humira (Uveitis) Expert Session, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
There was the right mix of presentation and discussion
The session addressed high priority issues for my market/asset
My views were heard and understood
It was valuable to participate in a discussion with HQ and Area/affiliate colleagues
I left the session with a clear view on next steps
 
 
 
Please provide additional feedback on any aspect of the Expert Sessions, and list any suggestions you have for improvements.
   
 
 
 
How much of the pre-reading did you complete in preparation for the Key Compound Breakout and Expert Session discussions? (Select one)
 
I read all of the pre-reading
 
I read most of the pre-reading
 
I read some of the pre-reading
 
I read none of the pre-reading
 
 
If you completed any of the pre-reading, we are interested in your experience. Please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
The pre-reading provided the context I needed to participate fully in the session
The pre-reading was clear and well written
The pre-reading was the right length and depth
The background information in the presentations could have been shorter because the pre-reading effectively covered the information
 
 
 
If you did not read all of the pre-reading, why were you unable to complete the material? (Please select all that apply)
 
I already had plenty of context on the market and AbbVie’s efforts in the area
 
I did not have time
 
I was not aware pre-reading was available
 
I could not access the pre-reading
 
I did not plan to attend the Key Compound Breakouts or Expert Sessions
 
Other (Please specify)
 

 
 
 
Do you have any suggestions on how to improve the pre-reading material or its use in the presentations? If so, please list them below.
   
 
 
 
How much of the homework did you complete in preparation for the Key Compound Breakouts and Expert Sessions discussions? (Please select one)
 
I read all of the homework
 
I read most of the homework
 
I read some of the homework
 
I read none of the homework
 
 
If you completed any of the homework, we are interested in your experience. Please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I knew enough background to complete the questions (from the pre-readings or elsewhere)
The instructions for the homework were clear and easy to follow
The number of homework questions that I had to complete was reasonable
I had sufficient time to complete the homework questions
I felt my homework submission was reviewed by the product team and constructively incorporated into the discussion
 
 
 
If you did not complete all of the homework, why were you unable to complete the review of the material? (Select all that apply)
 
I did not have the time
 
I was not aware the homework was available
 
I could not access the homework
 
I did not feel the homework would contribute meaningfully to discussion within the session
 
Other (Please specify)
 

 
 
 
Do you have any suggestions on how to improve the homework material or its use in the presentations? If so, please list them below.
   
 
 
 
Which Rapid Review Series did you attend? (Select up to 3 options)
 
ABT-110
 
ABT-981
 
ABT-436
 
ABT-419
 
ADC
 
DVD-Ig
 
Imaging Technologies
 
Corporate licensing / Acquisitioning & Commercial Business Development
 
Global Alliance Management
 
Global Health Economics and Outcomes Research / Global Value Proposition
 
Governance Review & Launch Playbook
 
Business Intelligence / Insights
 
Finding the next generation of targets
 
Global Forecasting
 
I did not attend a Rapid Review Series

 
 
 
Why did you choose to attend the specific Rapid Review Series listed?
 
I had more context about what was being presented
 
The topics were more interesting
 
The topics were more relevant for my job
 
The topics were more relevant for my region
 
Other (Please specify)
 
 
If you attended the ABT-110 Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I learned about a new asset that could have great potential in my market
I have a much broader understanding of AbbVie’s early-stage pipeline
I took away some exciting news about our pipeline that I will share with others
I identified a specific opportunity for collaboration
 
 
If you attended the ABT-981 Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I learned about a new asset that could have great potential in my market
I have a much broader understanding of AbbVie’s early-stage pipeline
I took away some exciting news about our pipeline that I will share with others
I identified a specific opportunity for collaboration
 
 
If you attended the ABT-436 Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I learned about a new asset that could have great potential in my market
I have a much broader understanding of AbbVie’s early-stage pipeline
I took away some exciting news about our pipeline that I will share with others
I identified a specific opportunity for collaboration
 
 
If you attended the ABT-419 Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I learned about a new asset that could have great potential in my market
I have a much broader understanding of AbbVie’s early-stage pipeline
I took away some exciting news about our pipeline that I will share with others
I identified a specific opportunity for collaboration
 
 
If you attended the ADC Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I have a greater appreciation for the technology used in AbbVie’s pipeline development
I have a much broader understanding of AbbVie’s early-stage pipeline
I took away some exciting news about our pipeline that I will share with others
I identified a specific opportunity for collaboration
 
 
If you attended the DVD-Ig Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I have a greater appreciation for the technology used in AbbVie’s pipeline development
I have a much broader understanding of AbbVie’s early-stage pipeline
I took away some exciting news about our pipeline that I will share with others
I identified a specific opportunity for collaboration
 
 
If you attended the Imaging Technology Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I have a greater appreciation for the technology used in AbbVie’s pipeline development
I have a much broader understanding of AbbVie’s early-stage pipeline
I took away some exciting news about our pipeline that I will share with others
I identified a specific opportunity for collaboration
 
 
If you attended the Corporate Licensing / Acquisitions & Commercial Business Development Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I gained a deeper understanding of this group’s role within AbbVie and how it contributes to pipeline development
I understand how Corporate Licensing / Acquisitions & Commercial Business Development can help my division achieve its goals
I identified a specific opportunity for collaboration
 
 
If you attended the Global Alliance Management Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I gained a deeper understanding of this group’s role within AbbVie and how it contributes to pipeline development
I understand how Global Alliance Management can help my division achieve its goals
I identified a specific opportunity for collaboration
 
 
If you attended the Global Health Economics and Outcomes Research Overview / Global Value Proposition Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I gained a deeper understanding of this group’s role within AbbVie and how it contributes to pipeline development
I understand how Global Health Economics and Outcomes Research Overview / Global Value Proposition can help my division achieve its goals
I identified a specific opportunity for collaboration
 
 
If you attended the Governance Review and Launch Playbook Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I gained a deeper understanding of this group’s role within AbbVie and how it contributes to pipeline development
I understand how Governance Review and Launch Playbook can help my division achieve its goals
I identified a specific opportunity for collaboration
 
 
If you attended the Business Intelligence / Insights Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I gained a deeper understanding of this group’s role within AbbVie and how it contributes to pipeline development
I understand how Business Intelligence / Insights can help my division achieve its goals
I identified a specific opportunity for collaboration
 
 
If you attended the Finding the Next Generation of Targets Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I gained a deeper understanding of this group’s role within AbbVie and how it contributes to pipeline development
I understand how Finding the Next Generation of Targets can help my division achieve its goals
I identified a specific opportunity for collaboration
 
 
If you attended the Global Forecasting Rapid Review Series, please rate your agreement with the following statements on a scale of 1 to 7.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I gained a deeper understanding of this group’s role within AbbVie and how it contributes to pipeline development
I understand how Global Forecasting can help my division achieve its goals
I identified a specific opportunity for collaboration
 
 
 
Please provide additional feedback on any aspect of the Rapid Review Series, and list any suggestions you have for improvements.
   
 
 
We are interested in your experience at the dinners and networking opportunities. Please rate your agreement with the following statements on a scale of 1 to 7, or select "N/A" for those items where you did not attend or do not have sufficient experience to judge.
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
I was able to meet new people and establish contacts that I will draw on in the future
I was able to reconnect with colleagues who I had not seen in a while
The ambiance enabled conversations and mingling
The number of networking opportunities felt appropriate given the nature of the event
 
 
On a scale of 1 to 7, please rate your experience as a whole along the following dimensions. Please select "N/A" for those items where you did not attend or do not have sufficient experience to judge.
N/A 1 = Not positive/Bad experience 2 3 4 = Neutral 5 6 7 = Very positive/ Excellent experience
Overall impression of the Key Compound Breakouts
Overall impression of the Expert Sessions
Overall impression of the Rapid Review Series
Meeting format/schedule
Quality of the content
Communication before and during meetings
Networking opportunities
Meeting location
Meeting facilities
Meeting logistics (e.g. registration, transportation)
 
 
Based on pre-meeting survey results, participants expected the Global Pipeline Summit to meet three important expectations. On a scale of 1 to 7, how well did the meeting meet these expectations?
1 = Strongly disagree 2 3 4 = Neutral 5 6 7 = Strongly agree
Helped inform plans for what capabilities will be needed, based on potential upcoming launches
Provided opportunity to engage in collaborative problem-solving
Provided deeper understanding of key opportunities and products in AbbVie’s pipeline
 
 
 
How frequently did you access the Global Pipeline Summit website to stay informed in preparation for the meeting? (Please select one)
 
Never (0 times)
 
1-2 times
 
3 or more times
 
 
 
What information did you access on the Global Pipeline Summit website? (Please choose all that apply)
 
I never accessed the website
 
Pre-reads and homework questions
 
Meeting agenda
 
Logistics and registration information
 
Contact lists
 
Other (Please specify)
 

 
 
 
What time of year is best to host future Global Pipeline Summit meetings? (Please select one)
 
Jan-Mar
 
Apr-Jun
 
Jul-Sep
 
Oct-Dec
 
 
 
What did you like most about the meeting?
   
 
 
 
What changes would you recommend to improve future meetings?
   
 
Survey Software Powered by QuestionPro Survey Software